Free Trial

Coloplast A/S (CLPBY) Stock Forecast & Price Target

Coloplast A/S logo
$12.60 -0.15 (-1.18%)
(As of 11/20/2024 ET)

Coloplast A/S - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
1
Buy
0

Based on 1 Wall Street analysts who have issued ratings for Coloplast A/S in the last 12 months, the stock has a consensus rating of "Hold." Out of the 1 analysts, 1 has given a hold rating for CLPBY.

Consensus Price Target

N/A

Get the Latest News and Ratings for CLPBY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Coloplast A/S and its competitors.

Sign Up

CLPBY Analyst Ratings Over Time

TypeCurrent Forecast
11/22/23 to 11/21/24
1 Month Ago
10/23/23 to 10/22/24
3 Months Ago
8/24/23 to 8/23/24
1 Year Ago
11/22/22 to 11/22/23
Strong Buy
0 Strong Buy rating(s)
N/A
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
0 Buy rating(s)
N/A
0 Buy rating(s)
1 Buy rating(s)
Hold
1 Hold rating(s)
N/A
2 Hold rating(s)
5 Hold rating(s)
Sell
0 Sell rating(s)
N/A
0 Sell rating(s)
1 Sell rating(s)
Consensus Price TargetN/AN/AN/AN/A
Forecasted UpsideN/AN/AN/AN/A
Consensus Rating
Hold
N/A
Hold
Hold

CLPBY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CLPBY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Coloplast A/S Stock vs. The Competition

TypeColoplast A/SMedical CompaniesS&P 500
Consensus Rating Score
0.00
2.80
2.50
Consensus RatingN/AModerate BuyModerate Buy
Predicted UpsideN/A26,931.54% Upside9.83% Upside
News Sentiment Rating
Neutral News

See Recent CLPBY News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/18/2024Hsbc Global Res
0 of 5 stars
S. Gupta
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeModerate Sell ➝ Hold
9/7/2023Royal Bank of Canada
4 of 5 stars
 Initiated CoverageSector Perform
9/5/2023The Goldman Sachs Group
2 of 5 stars
 Initiated CoverageNeutral
7/10/2023DNB Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy
6/1/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOverweight ➝ Equal Weight
5/12/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeNeutral ➝ Underweight
3/29/2023Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeUnderweight ➝ Equal Weight
3/7/2023Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageMarket Perform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 02:31 PM ET.


Should I Buy Coloplast A/S Stock? CLPBY Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, November 6, 2024. Please send any questions or comments about these Coloplast A/S pros and cons to contact@marketbeat.com.

Coloplast A/S
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Coloplast A/S:

  • Coloplast A/S stock price recently crossed below its 50-day moving average, potentially indicating a buying opportunity as the stock may be undervalued.
  • Coloplast A/S has a strong net margin of 18.89%, indicating efficient cost management and profitability.
  • Coloplast A/S reported a return on equity of 31.39%, showcasing the company's ability to generate profit from shareholders' equity.
  • Coloplast A/S has a market capitalization of $28.64 billion, reflecting the company's size and stability in the market.
  • Coloplast A/S has a diverse product portfolio in intimate healthcare products and services, providing a stable revenue stream across multiple markets.

Coloplast A/S
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Coloplast A/S for these reasons:

  • Coloplast A/S has a relatively high price-to-earnings ratio of 40.18, which may indicate that the stock is currently overvalued.
  • Coloplast A/S has a price-to-earnings-growth ratio of 3.45, suggesting that the stock may be expensive relative to its earnings growth potential.
  • Coloplast A/S has a beta of -0.01, indicating that the stock's price is not very sensitive to market movements, potentially leading to lower returns in volatile market conditions.
  • Coloplast A/S has a current ratio of 0.85 and a quick ratio of 0.56, which may raise concerns about the company's short-term liquidity and ability to meet immediate financial obligations.
  • Coloplast A/S operates in a competitive market for healthcare products and services, which could pose challenges in maintaining market share and profitability over the long term.

CLPBY Forecast - Frequently Asked Questions

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Coloplast A/S in the last year. There is currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" CLPBY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CLPBY, but not buy additional shares or sell existing shares.

According to analysts, Coloplast A/S's stock has a predicted downside of -100.00% based on their 12-month stock forecasts.

Over the previous 90 days, Coloplast A/S's stock had 1 upgrade by analysts.

Coloplast A/S has been rated by research analysts at Hsbc Global Res in the past 90 days.

Analysts like Coloplast A/S less than other "medical" companies. The consensus rating for Coloplast A/S is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how CLPBY compares to other companies.


This page (OTCMKTS:CLPBY) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners